Aastrom is developing ixmyelocel-T to treat patients with severe, chronic cardiovascular diseases, including critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). We will initiate a pivotal Phase 3 clinical trial (REVIVE) in patients with critical limb ischemia and who have no option for revascularization in Q4 2011. Contact us to learn more about Aastrom and the development of our patient-specific, multicellular therapies.
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!